June 2023 in “British Journal of Dermatology” In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” This study in a real-world setting found that baricitinib was effectively reducing disease severity in severe alopecia areata patients over 52 weeks, with 37.20% of participants achieving significant improvement and 72.40% experiencing mild or no adverse events.
10 citations
,
January 2023 in “Acta dermato-venereologica” In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.
March 2024 in “Current issues in molecular biology” This literature review explores the role of biomarkers in personalized medicine for various dermatological conditions like Hidradenitis Suppurativa, Psoriasis, and Atopic Dermatitis, highlighting how they guide targeted therapies and the limitations of current markers in specificity, as reported by the authors.
